Affinia raises $40m for gene remedy improvement
Gene remedy firm Affinia Therapeutics has raised $40m in a Sequence C funding spherical, led by New Enterprise Associates (NEA).
New investor Eli Lilly & Firm, together with earlier backers together with Mass Normal Brigham Ventures, Alexandria Enterprise Investments and Avidity Companions, additionally participated within the funding spherical.
Uncover B2B Advertising and marketing That Performs
Mix enterprise intelligence and editorial excellence to achieve engaged professionals throughout 36 main media platforms.
This financing will help the event of the corporate’s flagship programme, AFTX-201, aimed toward treating Bcl2-associated athanogene 3 (BAG3) dilated cardiomyopathy (DCM), an inherited coronary heart dysfunction recognized for its excessive loss of life price.
The capital inflow may even facilitate the development of the corporate’s gene remedy portfolio, which targets a spread of extreme illnesses.
Affinia Therapeutics CEO Rick Modi acknowledged: “We’re grateful to this excellent group of institutional and strategic buyers who share our pleasure about our novel, cardiotropic capsids and pipeline.
“This financing recognises the potential of our novel capsids and the worth of our lead programme AFTX-201, bringing it one step nearer to doubtlessly change into the first-in-class and best-in-class genetic drugs to deal with BAG3 DCM.”
Plans are in place for Affinia to file an investigational new drug (IND) software with the US Meals and Drug Administration (FDA) for AFTX-201 in late 2025.
If permitted, the corporate intends to begin the Part I/II UPBEAT trial for BAG3 DCM sufferers within the first quarter of 2026.
AFTX-201 is within the midst of IND-enabling research, which commenced following a pre-IND assembly with the US regulator.
AFTX-201, which is tailor-made to ship a totally human BAG3 transgene through a cardiotropic capsid of the corporate, goals for selective cardiac transduction at decrease doses.
It has enhanced the guts’s BAG3 protein ranges and restored cardiac operate in preclinical trials utilizing animal illness fashions. These outcomes weren’t replicated with a regular capsid on the identical dosage.
AFTX-201 is meant to be administered as a single intravenous dose.
Cell & Gene Remedy protection on Pharmaceutical Expertise is supported by Cytiva.
Editorial content material is independently produced and follows the highest requirements of journalistic integrity. Subject sponsors should not concerned within the creation of editorial content material.
Join our each day information round-up!
Give your small business an edge with our main business insights.
